Libtayo (cemiplimab)
Numéro de dossier de l’AMC:
22889
État des négociations:
En négociation
Indication(s):
Non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, first-line treatment of adult patients who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC
Promoteur/fabricant:
Regeneron
Numéro de projet de l’AMC:
Sans objet
Lettre-contrat de l’APP:
Conclusion du processus de négociation:
Sans objet